Genprex (GNPX) Stock Analysis: AI Score & Alternative Data
GNPX alt-data: headcount climbing, web traffic lagging
Is Genprex a buy right now? The alternative data says hold. This GNPX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Genprex every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $2.61 with a $2M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 9.1% to 24 employees. The drag: web traffic down 24.9% to 4K monthly visits. That tension is what keeps the score mid-range.
GNPX’s broader alt-data profile also covers Facebook followers (23K), and sentiment (95/100). Every signal links to its own page with full history, the GNPX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on GNPX is just below.
Genprex AI Stock Analysis
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's lead product candidate, Ongogene, is an immunogene therapy for non-small cell lung cancer (NSCLC).
Analysis generated October 2, 2026.
Recent Genprex Stock Alerts
|
Genprex | October 5 Price is up by 6.5% in the last 24h. |
|
Genprex | October 1 Price is down by -9.3% in the last 24h. |
|
Genprex | September 30 Price is up by 6.7% in the last 24h. |
|
Genprex | September 28 Price is down by -6.4% in the last 24h. |
Genprex Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 24.9% | |
| Job Posts | 0 | 100.0% | |
| LinkedIn Employees | 24 | 9.1% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 95 | 5.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 13 | 1,200.0% | |
| Stocktwits Mentions | 50 | 138.1% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 15K | 0.6% | |
| Facebook Followers | 23K | 0% | |
| Facebook Engagement | 1 | N/A |
About Genprex (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
| Price | $2.61 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2M |
| Year Range | $3 – $924 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Genprex News
View more → |
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyAugust 18 - PRNewswire |
 |
Genprex partners with Roche Diagnostics on biomarker validation for NSCLCAugust 4 - Biztoc.com |
 |
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation StudiesAugust 3 - PRNewswire |
 |
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsightJuly 2 - PRNewswire |
 |
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsightJune 15 - PRNewswire |
See Genprex’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for GNPX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEGenprex Earnings & Financial Performance
View all earnings →Genprex Insider Trading Activity
View all →| LONGNECKER BRENT M filed to sell 9,157 shares at $0.0. Apr 14 '26 |
| LONGNECKER BRENT M filed to sell 0 shares at $0.0. Apr 14 '26 |
Genprex Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Tim Moore |
Feb 23, 26 | Buy | $8K+ |
| Tim Moore |
Jan 8, 26 | Buy | $8K+ |
| Tim Moore |
Dec 3, 25 | Buy | $8K+ |
Stocks Similar to Genprex
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
OragenicsOGEN |
$0.49 0.2% | $2M | 52 |
 |
Clearside BiomedicalCLSD |
$0.41 27.0% | $2M | 45 |
 |
BioXcel TherapeuticsBTAI |
$0.07 37.1% | $2M | 45 |
 |
Alaunos TherapeuticsTCRT |
$0.74 6.6% | $2M | 48 |
 |
Clearmind Medicine Common SharesCMND |
$5.84 2.7% | $2M | 40 |
Explore Genprex Data
Frequently Asked Questions: Genprex (GNPX)
Genprex has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Genprex (GNPX) stock is $2.61 with a market cap of $2M.
As of today, Genprex’s PE (Price to Earnings) ratio is —.
View the latest Genprex insider transactions to see recent buying and selling activity by company executives and directors.
Check the Genprex congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The GNPX stock price chart above shows Genprex’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Genprex technical analysis for RSI, moving averages, and more.
See the stocks similar to Genprex section on this page for companies in the same industry ranked by market cap and AI Score.
